Sfoglia per AUTORE
VITALE C
Collezione ASL Asti

  

Items : 9

Increase of continuous treatments and regional citrate anticoagulation during renal replacement therapy in the ICUs of the North-West of Italy from 2007 to 2015. in Minerva urology and nephrology / Minerva Urol Nephrol. 2023 Jun;75(3):388-397. doi: 10.23736/S2724-6051.22.04699-7. Epub 2022 Mar 11.

2023
ASL Città di Torino
ASL Vercelli
ASL Asti
ASL Torino 4
ASL VCO
ASL Cuneo 1
ASL Cuneo 2
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino
ASL Alessandria
AOU Alessandria
ASL Novara

Roccatello D; Biancone L; Cusinato S; Besso L; Chiarinotti D; Manganaro M; Cesano G; Boero R; Vitale C; Filiberti O; Costantini L; Vio P; Borzumati M; Chiappero F; Todini V; Marciello A; Savoldi S; Deagostini C; Serra A; Martina G; Salomone M; Stramignoni E; Formica M; Gherzi M; Calabrese G; Roscini E; Marino A; Maffei S; Viglino G; et alii...

OBINUTUZUMAB PLUS CHLORAMBUCIL VERSUS IBRUTINIB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT TP53 DISRUPTIONS. A CAMPUS CLL STUDY in Haematologica

2021
ASL Asti

Visentin A; Pravato S; Mauro FR; Pietrasanta D; Fresa A; Vitale C; Ciolli S; Cassin R; Cibien F; Sportoletti P; Gentile M; Rigolin GM; Quaglia FM; Murru R; Gozzetti A; Molica S; Marchetti M; Scarfò L; Guardalben E; Avitabile A; Reda G; Coscia M; Laurenti L; Pizzolo G; Semenzato G; Foà R; Cuneo A; Trentin L;

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. in Haematologica / Haematologica. 2020 Apr;105(4):1042-1054. doi: 10.3324/haematol.2019.217430. Epub 2019 Jul 9.

2020
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
ASL Vercelli
AOU Novara

Boccadoro M; Gattei V; Foà R; Massaia M; Gaidano G; Zenz T; Bernardi R; Mauro FR; Laurenti L; Del Poeta G; Kodipad AA; Omedè P; Magliulo D; Rossi D; Marchetti M; Bonello L; Pozzato G; Bo MD; Kopecka J; Bomben R; Salvetti C; Riganti C; Todaro M; Vitale C; Griggio V; Coscia M;

Worldwide Examination of Patients with CLL Hospitalized for COVID-19 in Blood

2020
ASL Asti
AOU Città della Salute di Torino

Roeker LE; Scarfo L; Chatzikonstantinou T; Abrisqueta P; Eyre TA; Cordoba R; Muntañola Prat A; Villacampa G; Leslie LA; Koropsak M; Quaresmini G; Allan JN; Furman RR; Bhavsar EB; Pagel JM; Hernandez-Rivas JA; Patel K; Motta M; Bailey N; Miras F; Lamanna N; Alonso R; Osorio-Prendes S; Vitale C; Kamdar M; Baltasar P; Österborg A; Hanson L; Baile M; et alii...

Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus in Blood

2020
ASL Asti
AOU Città della Salute di Torino

Visentin A; Mauro FR; Pietrasanta D; Fresa A; Vitale C; Ciolli S; Cassin R; Cibien F; Sportoletti P; Gentile M; Rigolin GM; Quaglia FM; Murru R; Gozzetti A; Molica S; Marchetti M; Scarfo L; Reda G; Coscia M; Laurenti L; Pizzolo G; Semenzato G; Foà R; Cuneo A; Trentin L;

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia in Haematologica

2020
ASL Asti

Griggio V; Vitale C; Todaro M; Riganti C; Kopecka J; Salvetti C; Bomben R; Bo MD; Magliulo D; Rossi D; Pozzato G; Bonello L; Marchetti M; Omedè P; Kodipad AA; Laurenti L; Poeta GD; Mauro FR; Bernardi R; Zenz T; Gattei V; Gaidano G; Foà R; Massaia M; Boccadoro M; Coscia M;

HIF-1? is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia in Haematologica

2020
ASL Asti

Griggio V; Vitale C; Todaro M; Riganti C; Kopecka J; Salvetti C; Bomben R; Bo MD; Magliulo D; Rossi D; Pozzato G; Bonello L; Marchetti M; Omedè P; Kodipad AA; Laurenti L; Poeta GD; Mauro FR; Bernardi R; Zenz T; Gattei V; Gaidano G; Foà R; Massaia M; Boccadoro M; Coscia M;

Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs in Blood

2019
ASL Asti
AOU Città della Salute di Torino

Vitale C; Salvetti C; Griggio V; Scamuffa MC; Zamprogna G; Visentin A; Cassin R; Laurenti L; Murru R; Rivela P; Marchetti M; Gentile M; Pennese E; Reda G; Trentin L; Tedeschi A; Mauro FR; Foà R; Boccadoro M; Coscia M;

The hypoxia-inducible factor-1alpha is constitutively upregulated in TP53 disrupted CLL cells: A potential target to overcome fludarabine resistance in Blood

2015
AO Ordine Mauriziano
ASL Asti

Griggio V; Vitale C; Riganti C; Kopecka J; Dal Bo M; Rossi D; Pozzato G; Laurenti L; Zallio F; Marchetti M; Ruggeri M; Omedè P; Del Poeta G; Gattei V; Gaidano G; Boccadoro M; Massaia M; Coscia M;